stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Price to free cash flow
As of 5 November 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a price to free cash flow of 9.9×. Over the past ten years it has ranged from 7.4× (October 2020) to 21.0× (April 2017); the current reading is higher than 28% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2026 | 11.7× | (33.64%) |
| FY2025 | 17.6× | 17.86% |
| FY2024 | 14.9× | 5.83% |
| FY2023 | 14.1× | 32.43% |
| FY2022 | 10.6× | 2.48% |
| FY2021 | 10.4× | 12.94% |
| FY2020 | 9.2× | 7.46% |
| FY2019 | 8.5× | (3.63%) |
| FY2018 | 8.9× | (56.07%) |
| FY2017 | 20.2× | 24.08% |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 10.2× | 6.69% |
| Jun 2026 | 9.5× | (18.20%) |
| Mar 2026 | 11.7× | 5.41% |
| Dec 2025 | 11.1× | (7.69%) |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ALVO Alvotech compare | n/m |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| AMLX Amylyx Pharmaceuticals, Inc. compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 5.3× |
| PBH Prestige Consumer Healthcare Inc. | 9.9× |
| TRLV Trulieve Cannabis Corp. compare | 11.8× |
| PRGO Perrigo Company plc compare | 12.4× |
| XERS Xeris Biopharma Holdings, Inc. compare | 32.2× |
| Drug Manufacturers Specialty & Generic industry median | 16.3× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement